FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to solid pharmaceutical composition containing risedronate for oral administration. Composition has risedronate as an active component and coated with enterosoluble envelope consisting of anionic carboxylic polymer (thickness is 20-100 mcm). Invention provides possibility to decrease risk of esophagitis arising or esophagus irritation that can associate with oral risedronate administration sometimes. EFFECT: improved quality of composition. 8 cl
Authors
Dates
1998-10-27—Published
1992-11-02—Filed